Genmab — December 2018
-
Markederne er negative, men er der ikke mere styrke og modstandskraft i disse dage i Genmab end der har været i lang tid?
-
-
Nordea har vist også været gode købere i nogle af dagene.
-
Det vil vel være perfekt på onsdag sammen med gode tal om formiddagen
-
short video -
Results of using dara-CyBorD to treat patients with newly diagnosed or relapsed multiple myeloma - https://www.youtube.com/watch?v=teFY_GcOzfA -
-
Dara ranks second in the Trinity Partners FDA-Approved 2015 Drug Performance Index https://www.businesswire.com/news/home/20181217005147/en/ and pdf report http://www.trinitypartners.com/files/2015/4463/5016/2018_Trinity_Drug_Index_-_Trinity_Partners.pdf
-
-
-
NBI spiller sjældent ind overfor genmab. Den følger tit Dax eller den generelle markedsstemning. GMXAY er heller ikke vigtig. Se igen på en meget lille omsætning. Det spille ikke ind og kan ikke tages som et udtryk for noget. Vi starter nok i rødt igen og er vi heldige ender vi omkring O.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind